Pay in installments of $73.12 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
DLL3 Recombinant Rabbit mAb,PBS Only (S-207-179)Product Specification Host Rabbit Antigen DLL3 Synonyms Delta like protein 3, Drosophila Delta homolog 3 (Delta3) Immunogen Synthetic Peptide Location Cytoplasm Accession Q9NYJ7 Clone Number S 207 179 Antibody Type Recombinant mAb Isotype IgG Application WB, IHC P Reactivity Hu Purification Protein A Concentration 1 mg ml Conjugation Unconjugated Physical Appearance Liquid Storage Buffer PBS Stability & Storage 12 months from date of receipt
Product Specification
| Host | Rabbit |
| Antigen | DLL3 |
| Synonyms | Delta-like protein 3, Drosophila Delta homolog 3 (Delta3) |
| Immunogen | Synthetic Peptide |
| Location | Cytoplasm |
| Accession | Q9NYJ7 |
| Clone Number | S-207-179 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB, IHC-P |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS |
| Stability & Storage | 12 months from date of receipt / reconstitution,4 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | |
| IHC-P | 1:500 |
Background
DLL3, or Delta-like ligand 3, is a protein that is overexpressed in a significant proportion of small cell lung cancer (SCLC) tumors. It is a type of ligand that interacts with the Notch signaling pathway, which is involved in cell differentiation and proliferation. DLL3 is considered an attractive target for cancer therapies because of its limited expression in normal tissues, which may reduce the risk of on-target, off-tumor toxicity. Therapeutic strategies targeting DLL3 include antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies. These approaches aim to direct immune cells to DLL3-expressing cancer cells, leading to their destruction. Notably, DLL3-targeted therapies are in various stages of clinical development, with some showing promise in early-phase trials for the treatment of SCLC, which has limited treatment options and a generally poor prognosis. The development of DLL3-targeted therapies represents a significant effort to improve outcomes for patients with this aggressive form of lung cancer.
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy